safety and tolerability study of AZD7762 in combination with gemcitabine

Study identifier:D1040C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies

Medical condition

cancer

Phase

Phase 1

Healthy volunteers

Study drug

AZD7762, gemcitabine

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 74 Years

Date

Study Start Date: 01 Jul 2009

Estimated Primary Completion Date: 01 Feb 2011

Estimated Study Completion Date: 01 Feb 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Other: AZD7762 + gemcitabine AZD7762 administered alone and in combination with gemcitabine	Drug: AZD7762 solution, intravenous, weekly Drug: gemcitabine intravenous, weekly Other Name: Gemzar

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1715&filename=CSP-D1040C00008.pdf
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1715&filename=CSR-D1040C00008.pdf
Download
CSP-D1040C00008.pdf
Download
CSR-D1040C00008.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Peter Langmuir

AstraZeneca

safety and tolerability study of AZD7762 in combination with gemcitabine

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1715&filename=CSP-D1040C00008.pdf

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1715&filename=CSR-D1040C00008.pdf

CSP-D1040C00008.pdf

CSR-D1040C00008.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator